REG - Futura Medical PLC - Block listing Interim Review

Futura MedicalAnnouncement

30/05/2019 07:05

RNS Number : 5327A
Futura Medical PLC
30 May 2019
 









 
 
                                                   
 
 
 
30 May 2019



 
 
Futura Medical plc (AIM: FUM)
("Futura" or "the Company")
 
Block Listing Update
 
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).
The table below provides further detail.
 



Name of company:


Futura Medical plc












Name of scheme(s):


Unapproved Share Option Scheme ("USOS")
Unapproved Share Incentive Scheme  ("USIS")
EMI Share Option Scheme ("EMI")












Period of return:


From:


1 December 2018












To:


30 May 2019












 
Number and class of securities not issued under the scheme(s) at beginning of period


 
USOS:


 
1,993,875












USIS:


425,000












EMI:


3,806,125












Total:


6,225,000












Number and class of securities admitted to the scheme(s) in the period


USOS:


-












USIS:


-












EMI:


-












Total:


-












Number of securities issued under the scheme(s) during the period


USOS:


-












USIS:


-












EMI:


-












Total:


-












Number of securities lapsed under the scheme(s) during the period


USOS:


-












USIS:


-












EMI:


-












Total:


-












Balance of securities under the scheme(s) not yet issued at the end of the period


USOS:


1,993,875












USIS:


425,000












EMI:


3,806,125












Total:


6,225,000
























 




 
Number and class of securities originally admitted and the date of admission


 
USOS:


 



814,424


25 May 2011,




1,202,280


8 October 2013,




1,466,208


25 May 2017,




400,000


30 May 2018,



 




USOS Total:


        3,882,912












 USIS:





425,000


30 November 2018



 


 
 
 








USIS Total:


425,000












EMI:





1,520,576


25 May 2011,




1,467,720


8 October 2013,




1,893,792


25 May 2017,




790,000


30 May 2018,




1,340,000


30 November 2018
















EMI Total:


7,012,088






























Total:


11,320,000





























































For further information please contact:
Futura Medical plc 

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670



Liberum (Nominated Adviser and Broker)
Bidhi Bhoma

Euan Brown

Kane Collings

Tel: +44 (0) 20 3100 2000
 
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Ellie Blackwell
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
 
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
 
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRBRGDUSDDBGCC